Continuous Bioprocessing Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Page: 215 | Report Code: LS241023 | Research Suite: Report (PDF) & Market Data (Excel)

NOTE: Due to exhaustive nature of content, full ToC can't be uploaded. Please request Sample Pages to receive full table of content. 

Continuous bioprocessing is a bioprocessing manufacturing strategy in which biological production activities are carried out continuously instead of in discrete batches. This technique allows materials to move through the production process without interruption, which is able to enhance productivity and cut down on processing times and operating expenses.

MARKET OVERVIEW

The continuous bioprocessing market is valued at approximately USD 218 million in 2023 and is projected to reach USD 2013.97 million by 2034 exhibiting a compound annual growth rate (CAGR) of 22.4% during the forecast period of 2024-2034. Continuous bioprocessing maximizes resource utilization and reduces waste by fusing upstream and downstream processes into a smooth workflow.


GROWTH DRIVERS

The market for continuous bioprocessing is primarily influenced by the rising demand for biopharmaceuticals. Biologics, which are capable of targeting particular diseases with fewer side effects than traditional medications, are becoming increasingly more necessary as the healthcare environment changes. For instance, the use of monoclonal antibodies (mAbs) is increasingly becoming popular due to their effectiveness in treating chronic diseases such as cancer and autoimmune disorders. According to the U.S. FDA report, biologics accounted for 40.5% of all authorized medications in 2022, demonstrating a strong trend toward biopharmaceuticals.

Continuous bioprocessing has a number of benefits over fed-batch or batch processing techniques. These advantages include increased productivity, better product uniformity, and less downtime in between manufacturing cycles. For example, continuous flow production is able to improve product uniformity across batches, decrease buffer usage, and cut manufacturing costs. Due to its operational efficiency, continuous bioprocessing is a desirable and popular alternative for manufacturing companies seeking to streamline their manufacturing processes.

The continuous bioprocessing market’s growth is further fueled by the emergence of integrated end-to-end solutions, technological advancements, regulatory support promoting adoption, and a focus on cost reduction.

MARKET SEGMENTATION:

By Product -

·         Chromatography Systems and Consumables

·         Filtration Systems and Devices

·         Bioreactors

·         Consumables

o   Cell Culture Media & Buffers

o   Reagents

·         Other Products

By Scale of Operation -

·         Commercial Operations

·         Clinical Operations

By Process -

·         Downstream Process

·         Upstream Process

By Application -

·         Monoclonal Antibodies

·         Vaccines

·         Cell & Gene Therapy

·         Other Applications

By End User -

·         Pharmaceutical & Biotechnology Companies

·         Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)

·         Academic & Research Institutes

By Region -

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Continuous Bioprocessing Market By Product Segment Review:

The segment of filtration systems and devices dominated the global market for continuous bioprocessing. The market demand of this segment is growing due to the growing emphasis on process efficiency and product quality assurance within biomanufacturing environments.


Continuous Bioprocessing Market By Scale of Operation Segment Review:

Commercial operations are large-scale manufacturing procedures designed to produce biopharmaceuticals in significant quantities that are prepared for distribution on the market. In order to maintain regulatory compliance and maximize output, the commercial segment is distinguished by large investments in technology and infrastructure.

Continuous Bioprocessing Market By Process Segment Review:

The downstream process of continuous bioprocessing encompasses the stages that occur following the biologic production of a desired product, such as proteins, enzymes, or other biomolecules. The downstream segment is growing due to the increased demand for high-purity biopharmaceuticals and advancements in purification technologies that allow for more efficient processing.

Continuous Bioprocessing Market By Application Segment Review:

Modern biopharmaceuticals rely heavily on monoclonal antibodies (mAbs). Monoclonal antibodies are in high demand worldwide because of their ability to treat a wide range of diseases, especially autoimmune diseases and cancers.

Continuous Bioprocessing Market By End User Segment Review:

The pharmaceutical and biotechnology sectors are the major end user in the continuous bioprocessing market. The demand for biopharmaceuticals is on the rise in the pharmaceutical and biotechnology sectors due to their effectiveness in treating chronic diseases and conditions such as cancer, autoimmune disorders, and infectious diseases.

Continuous Bioprocessing Market By Region Segment Review:

The North America region is anticipated to hold the largest market share for continuous bioprocessing due to the well-established biopharmaceutical industry, and significant investment in research and development. The Asia Pacific market is anticipated to grow rapidly during the forecast period due to region’s increasing investments in biotechnology and pharmaceuticals.

Continuous Bioprocessing Market Regional Synopsis:

North America is expected to dominate the continuous bioprocessing market due to region’s well-established biopharmaceutical manufacturing base, and numerous government initiatives aimed at supporting its adoption.

Europe is another well-established player in continuous bioprocessing market. It is growing due to region’s strong regulatory support and increasing investment in research and development for biologics.

The Asia Pacific market is expected to grow at the maximum rate during the forecast period due to their rapid industrialization, various government initiatives, and increasing investments in biotechnology and pharmaceuticals.

The market in Latin America is growing due to the rising prevalence of chronic diseases, which is driving the demand for biologics. The growth of this market is expected to further impacted by government initiatives supporting biotechnology development, and technological advancements facilitating efficient production processes.

The Middle East & African market is witnessing growth potential due to surge in investments aimed at developing novel biologics, advanced therapies, and personalized medicine.


Continuous Bioprocessing Market Key Challenges:

The cost of initial setup for continuous bioprocessing is significant because of the need for advanced equipment such as specialized bioreactors, chromatography systems, and automation technologies. The high capital requirements often make it particularly challenging for smaller players in the market to enter. The requirement for economic research before purchasing continuous production equipment is likely to deter prospective manufacturers that lack the necessary funds or resources.

The complex processes involved in continuous bioprocessing necessitate the real-time monitoring and management of numerous crucial parameters and quality features. The integration of upstream and downstream processes in a continuous mode is complex and presents various challenges. For instance, while batch processing is generally considered less complicated, continuous systems require advanced technologies like sophisticated automation and process control technologies to effectively manage the flow of materials. This complexity increases the risks of failure if not managed properly.

Continuous Bioprocessing Market Competitive Landscape:

The global market for Continuous Bioprocessing is characterized by a mix of established companies and emerging firms, each striving to enhance their competitive edge.

The primary focus of key players in this market is on developing and providing advanced technologies and solutions that improve efficiency and effectiveness of biopharmaceutical manufacturing processes. They often establish strategic partnerships and collaborations to improve their product offerings and reaching a wider audience. For instance, in August 2023, Sartorius collaborated with Repligen Corporation to launch integrated bioreactor system that integrates Repligen XCell® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor to simplify the process of intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

Continuous Bioprocessing Market Key Players:

·         3M

·         Repligen Corporation

·         Bionet

·         Sartorius AG

·         Thermo Fisher Scientific Inc.

·         WuXi Biologics

·         Corning Incorporated

·         Integris

·         Esco Lifesciences Group

·         Getinge AB

·         Other Key & Niche Players

Buy Report

  • $1990
  • $2990